Loading data for TSHA — first visit, this takes a few seconds.
Taysha Gene Therapies, Inc.
5.16 +0.09 (1.78%)
5.10 +0.59%
- Market Cap
- $1.65B
- Volume
- 3.15M
- Dividend yield
- n/a
- Next earnings date
- Nov 4, 2026
Taysha Gene Therapies, Inc. (TSHA) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | -100.00% |
| EPS | -$0.13 | -$0.02 | -62.50% |
Metrics
- Bid
- 5.16
- Market Cap
- 1.65B
- Revenue (ttm)
- 5.49M
- Net Income (ttm)
- -150M
- 1.17
- -0.41
- n/a
- -10.96
- P/B (ttm)
- 6.87
- P/S (ttm)
- 301.18
- Earnings Date
- Nov 4, 2026
- Ask
- 6.51
- Volume
- 3,148,132
- Avg. Volume (20D)
- 3,211,585
- Open
- 5.25
- Previous Close
- 5.07
- Day's Range
- 5.05 - 5.46
- 52-Week Range
- 2.71 - 7.30
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Taysha Gene Therapies, Inc.
View profile →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Industry Biotechnology
Sector Healthcare
IPO Date Sep 24, 2020
Employees 99
Stock Exchange NasdaqGS
Ticker Symbol TSHA
Website https://www.tayshagtx.com